Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype.
about
MicroRNAs targeting prostate cancer stem cellsTargeting Head and Neck Cancer Stem Cells: Current Advances and Future ChallengesSelective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway.CD44v3+/CD24- cells possess cancer stem cell-like properties in human oral squamous cell carcinomaOverexpression of molecular chaperons GRP78 and GRP94 in CD44(hi)/CD24(lo) breast cancer stem cells.Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: Potential application for therapeutic targeting.New insights into the unfolded protein response in stem cells.PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway.Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potentialTransketolase Serves a Poor Prognosticator in Esophageal Cancer by Promoting Cell Invasion via Epithelial-Mesenchymal Transition.Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cells.A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy.MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44.Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells.Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer.
P2860
Q28081039-C10761FF-D3E8-40EF-961E-6BE2DA864B04Q33793000-B12A8260-85F3-4385-A1EF-CAB1808B267BQ34104084-E4BAAA94-7CA1-43DF-8525-90E795C6F861Q34252160-25891D1C-6FF5-4297-8C35-4A5A79FEF341Q36525387-F9D39626-1242-4C2E-975E-52D9F8D138B0Q37167969-81FEFED3-845C-47F7-8423-C260468A71E7Q37407142-98DB38EF-8002-471E-929B-2DEF8DA88C8AQ37619863-0B8C7D1B-46FF-47ED-9FB2-8D8B5F4F4820Q37656960-50EB20CF-59AE-4B82-B664-4CA68E5CF297Q37702121-55FF31AD-4170-4845-B861-2F5C47FD415EQ38198491-B24DD0EC-2186-4177-82A6-30368FF6FA74Q38742604-782D3A82-DE19-4391-929B-1F3D07B5B935Q38862494-3AD9C13D-DC82-42ED-AEDC-B9187B2AF8D2Q41308391-F9AE6701-5B87-49E3-A978-0FB00AC17886Q42259492-861C7193-529D-4D6B-B36B-FA5913580CC7Q46475690-61649D7C-7E71-4A33-BC8C-96154FD12BA0Q48167950-291D66A4-CBBE-4A6E-BCEB-8860187A2FC9Q49334888-38E9AA92-BAFE-4A53-A94D-71B242F2F272
P2860
Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Grp78 as a therapeutic target for refractory head-neck cancer with CD24
@nl
Grp78 as a therapeutic target ...... (-)CD44(+) stemness phenotype.
@en
type
label
Grp78 as a therapeutic target for refractory head-neck cancer with CD24
@nl
Grp78 as a therapeutic target ...... (-)CD44(+) stemness phenotype.
@en
prefLabel
Grp78 as a therapeutic target for refractory head-neck cancer with CD24
@nl
Grp78 as a therapeutic target ...... (-)CD44(+) stemness phenotype.
@en
P2093
P2860
P356
P1433
P1476
Grp78 as a therapeutic target ...... 4(-)CD44(+) stemness phenotype
@en
P2093
P2860
P2888
P304
P356
10.1038/CGT.2013.64
P577
2013-11-08T00:00:00Z